Zomedica (NYSE: ZOMDF) CEO adds 250,000 shares in open-market buy

Rhea-AI Filing Summary

Zomedica Corp. CEO and director Larry C. Heaton II reported an open-market purchase of 250,000 shares of the company’s common stock at $0.11 per share. Following this transaction, his direct ownership increased to 1,250,000 common shares.

Insider Trade Summary

Net Buyer: 250,000 shares ($27,500)

Net Buy 1 txn

Insider HEATON LARRY C II

Role CEO

Bought 250,000 shs ($28K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, without par value	250,000	$0.11	$28K

Holdings After Transaction: Common Stock, without par value — 1,250,000 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 250,000 shares Purchase price: $0.11 per share Estimated transaction value: $27,500 +1 more

4 metrics

Shares purchased 250,000 shares Open-market purchase of common stock

Purchase price $0.11 per share Price paid for the 250,000 common shares

Estimated transaction value $27,500 250,000 shares at $0.11 per share

Shares owned after transaction 1,250,000 shares CEO’s direct holdings following the purchase

Key Terms

open-market purchase, Common Stock, without par value, Form 4

3 terms

open-market purchase financial

"transaction_action": "open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock, without par value financial

"security_title": "Common Stock, without par value"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEATON LARRY C II

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE

STE 100

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ TSSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, without par value	05/08/2026		P		250,000	A	$0.11	1,250,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Larry C. Heaton II	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Zomedica (ZOMDF) disclose in this Form 4?

Zomedica disclosed that CEO Larry C. Heaton II executed an open-market purchase of 250,000 shares of common stock. The transaction involved non-derivative common shares and reflects a direct acquisition rather than an option exercise or derivative-related activity.

How many Zomedica (ZOMDF) shares did the CEO buy and at what price?

The CEO bought 250,000 Zomedica common shares at a price of $0.11 per share. This open-market purchase represents a cash investment into the stock at that trading level, as reported in the Form 4 insider filing.

What is Zomedica (ZOMDF) CEO Larry Heaton’s stake after this transaction?

After the reported purchase, Larry C. Heaton II directly owns 1,250,000 shares of Zomedica common stock. This total reflects his holdings immediately following the 250,000-share open-market acquisition reported in the Form 4 filing.

Is the Zomedica (ZOMDF) CEO’s trade an open-market purchase or option exercise?

The transaction is classified as an open-market purchase of common stock, coded as “P” in the Form 4. It does not involve options or other derivatives, and there are no related derivative exercises disclosed in this particular filing.

Does this Zomedica (ZOMDF) Form 4 show any insider share sales?

No insider share sales are reported in this Form 4. The transaction summary indicates one net buy transaction totaling 250,000 shares, with zero reported sales, gifts, tax withholdings, or restructuring-related dispositions in the filing.